GlassScriptPhysician profile
Amy A Simpson-Waid
NPI 1710209184
$7,515.59
in general payments reported to CMS, 2019-2025
41 companies · $1,584 in 2025
The $1,584 reported for 2025 was more than what 93% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,449 · 2022: $1,593 · 2023: $1,578 · 2024: $1,311 · 2025: $1,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,473.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $844.26 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $813.10 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $732.46 | 2021-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $696.00 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $534.45 | 2021-2025 | |
| Novo Nordisk INC | $534.43 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Sumitomo Pharma America, INC. | $336.71 | 2023-2025 | Gemtesa |
| Abbott Laboratories | $292.28 | 2021-2025 | Freestyle Libre |
| Bayer Healthcare Pharmaceuticals INC. | $281.78 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.45 | 2021-2024 | Jardiance, Ofev |
| Pfizer INC. | $232.36 | 2021-2025 | |
| Astellas Pharma US INC | $232.07 | 2021-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $212.81 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $189.38 | 2024-2025 | Caplyta |
| Grt US Holding, INC. | $157.98 | 2021-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Simpson-Waid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.